Making $$
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice L2 lineup on THMG...
mms looking to buy some shares from those who need XMAS $$
Lazarus
downticks too ....
didnt they have a rs awhile back?
now an fs.
looks like an act of desperation.
Lazarus
well i got THING 1 and THING 2 helping me....
...they came free in my Sugar Smacks.
http://www.kelloggs.com/promotions/cat_in_the_hat/plush.html
Lazarus
KSHR now asking a nickle /em
SIZING UP SMALL CAPS, Out of Steam?
By RHONDA BRAMMER
AS EVEN A VISITING Martian could tell you, this year has been dynamite for stocks. The venerable S&P 500, for example, is ahead a cool 22%. And that's small beer compared with the smoking surge of smaller stocks: In the past 11-plus months, the Russell 2000, a great proxy for small-cap performance, has rocketed higher by an awesome 43%.
Years in which small caps outperform by a wide margin in a strong market do not grow on trees. To find out just how rare they are, Merrill Lynch's chief small-cap strategist, Satya Pradhuman, went back all the way to 1926. Take a guess: How many years has the market as whole, as measured by the performance of large caps, risen 20% or more, while small stocks outpaced big ones by at least 10%?
Answer: only five times -- 1933, 1945, 1958, 1975 and 1991.
More to the point, perhaps, Pradhuman looked at what happened after those blockbuster years. Following all five, there was a January effect. That is, small stocks continued to outpace large ones in that single month, and usually, though not always, held the lead through the year as a whole.
However -- and this is a pretty big however -- returns in the year after the super outperformance were substantially lower. In fact, only once, in 1975-76, did both large and small stocks post double-digit returns two years running.
Small companies benefit most from easy and plentiful capital, Pradhuman argues, so that should translate into relatively better earnings and stock performance in 2004, with small caps outperforming by 6%-8%.
Small caps, of course, are our special pets and we hope he's right. But we have our doubts. The small-cap cycle is fairly long in the tooth, relative valuations are a whole lot less compelling than they were a year ago and there's a worrisome speculative flavor to much of this year's run-up in small issues.
In bad markets and good, small caps have been outperforming for 4.7 years now. The average small-cap cycle, going back to the 1930s, lasts 5.7 years. The longest by far, which began in 1975 and ended in 1983, lasted an amazing 8.5 years, but the 1991-94 span of small-cap outperformance was kaput in a mere 3.3 years.
Steven DeSanctis, Prudential's small-cap strategist (who did the work on cycles cited in the previous paragraph), contends that sometime in 2004, big caps will take the lead.
Compared with big stocks, small caps just aren't cheap anymore, whether you use as a yardstick relative P/E ratios, price-to-sales ratios or P/Es to growth rates. The median valuation of small stocks compared with large ones on all of those metrics, DeSanctis observes, is now above the long-term average.
What's more, small-cap earnings growth, which has outpaced big-cap profit growth in 13 of the past 14 quarters, is losing its edge. In the third quarter, profits of Prudential's small-cap universe rose a splendid 19.1%, but net for Prudential's large-cap universe was up nearly as much, at 18.3%.
If, as now seems inevitable, the Fed starts to jack up interest rates next year, that, says DeSanctis, will spell the end of small-cap dominance.
Makes sense to us.
crossing my fingers and hoping the knife doesnt drop through my hands.
Lazarus
looks pretty ugly here huh?
im starting my position.
Lazarus
they did take out all the shares i offered for sale @ .045
Lazarus
yep :)
they pretty much got full control of the paper since the OS is only around 5 million+ and the fully diluted number - 25 million likely represents a convertible loan.
anyway - hope they run it TO THE MOON!
Lazarus
Here is some news on IACG which we were chatting about last week. if you recall i said they were essentiall a shell that was looking to do a deal.
____________________________________
InterActive Group and Arrowhead Research Announce Agreement
Friday December 12, 8:30 am ET
HUMBOLDT, S.D., and PASADENA, Calif., Dec. 12 /PRNewswire-FirstCall/ -- InterActive Group, Inc. (OTC Bulletin Board: IACG - News), a Delaware corporation (the "Company") whose common stock is traded in the over-the-counter market and quoted on the NASD Electronic Bulletin Board under the symbol "IACG.OB", and Arrowhead Research Corporation, a privately-owned California corporation ("Arrowhead Research"), today announced the execution of a definitive Stock Purchase and Exchange Agreement (the "Exchange Agreement") pursuant to which, among other things, Arrowhead Research would become a wholly-owned subsidiary of the Company and the former shareholders of Arrowhead Research would acquire approximately 88.9% of the Company's Common Stock.
ADVERTISEMENT
Arrowhead Research was formed in May 2003, and completed a private placement in October 2003, selling shares of its common stock and warrants to purchase common stock for an aggregate of $2,645,000. Arrowhead Research has recently initiated its plan of proposed operations, which involves financing research projects primarily in the area of the development "nano" technologies and applications, by entering into arrangements with the California Institute of Technology in Pasadena, California ("CalTech"), and two individual professors on the faculty of CalTech.
Subject to the satisfaction of a number of conditions precedent set forth in the Exchange Agreement, the Exchange Agreement contemplates the completion of several transactions prior to closing, with the result that an aggregate of 705,635 shares of the Company's common stock would then be outstanding immediately prior thereto. The contemplated transactions include the following:
There will be a 1-for-65 "reverse split" of the Company's outstanding common and a 1-for-6.5 "reverse split" of the Company's outstanding preferred stock, which would reduce from a total of 25,276,000 to a total of 388,862 the number of shares of the Company's common stock outstanding. Although approval of the Company's stockholders is required to amend its Certificate of Incorporation to effect the "reverse split", the officers and directors of the Company, who together hold a majority of the votes entitled to be cast on the matter, have indicated that they will vote in favor of the "reverse split." Accordingly, approval of the "reverse split" is assured and proxies will not be solicited from the Company's Stockholders. However, an Information Statement to be filed with the Securities and Exchange Commission will be sent to each of the Company's stockholders of record at least 20 calendar days before the "reverse split" becomes effective.
The Company will acquire certain intellectual property from San Diego Magnetics, Inc. ("SDM"), whose majority shareholder, TPR Group, Inc., is also the principal stockholder of the Company. SDM was incorporated in 1998 to acquire from Eastman Kodak Company ("Kodak") the assets and properties then employed by Kodak in the ownership and activities of the Kodak San Diego Laboratories, a research and development operation in San Diego, California involved in the areas of thin film, specialty micro and nano devices and detectors. In connection with the acquisition, SDM obtained a non-exclusive right and license to use, for research, development and commercial purposes, a portfolio of patents owned by Kodak (the "Kodak Patents") that had been developed by Kodak, through its Kodak San Diego Laboratories and otherwise. In August 2003, a portion of its intellectual property relating to currency handling products was sold by SDM to a third party. The balance of the SDM intellectual property will be transferred to the Company.
The Company also is obligated to obtain the conversion and/or cancellation of more than $1,800,000 of the Company's outstanding debt, pursuant to agreements to be entered into with the holders thereof, leaving the Company with liabilities not to exceed $150,000.
In connection with the acquisition of the SDM technology and the conversion and/or cancellation of the Company's debt, a total of 316,773 shares of the Company's common stock, and warrants to purchase an additional 658,583 shares of the Company's common stock, at $1.50 per share, would be issued.
At the closing, the Exchange Agreement provides for the issuance of 5,655,000 shares of the Company's common stock, and warrants to purchase an additional 5,645,000 shares of common stock, at the price of $1.50 per share, to acquire all of the issued and outstanding common stock and warrants to purchase common stock of Arrowhead Research. Arrowhead Research would thereby become a wholly-owned subsidiary of the Company, whose corporate name would be changed to "Arrowhead Research Corporation", with the former shareholders of the old Arrowhead Research owning 5,655,000 shares, or approximately 88.9%, and the stockholders of the Company (including those obtaining shares in connection with the acquisition of the SDM technology and the debt cancellation and conversions) owning approximately 11.1%, of the 6,350,635 shares of the Company's common stock that would then be outstanding (before taking into account any exercises of warrants that would then be outstanding).
The Exchange Agreement also specifies that the current officers and directors of the Company resign all of their respective offices, to be replaced by designees of Arrowhead Research, effective as of the closing of the transactions contemplated thereby.
The shares of common stock and warrants to be received by the shareholders of Arrowhead Research will be issued by Registrant without registration under the Securities Act of 1933, as amended (the "Securities Act"). However, the Exchange Agreement provides that, as soon as practicable following issuance, the Company would be required to file a registration statement with the Securities and Exchange Commission for the purpose of registering for resale under the Securities Act all of these shares and warrants, as well as all of the shares and warrants issued without registration under the Securities Act in connection with the acquisition of the SDM technology and the cancellation and/or conversion of the Company's debt.
____________________________________
nano nano
Lazarus
penny market looks anemic today...
...actually - its been looking that way for a couple of weeks
Lazarus
i have been accumulating some select grey sheet stocks...
...but to date have never made any money off of them.
Lazarus
welcome to the pinkies...
...lots of money to be made here.
recent volume in pinky SIBM now understood --- stock is on the OTC:BB today!
Lazarus
pinky shell SIBM graduates to OTC:BB...
...would like to see CJCL do the same.
Lazarus
thanks... 18500 left to go ...
im outa here
well if they want to run it they will have to take out my GTC order to sell 34k shares at .045.
im in at under a penny and a half [my last buy was 20k at .01 only a few days ago] and there just isnt many shares in the float. if they dont want to take me out -- no problem... i can wait until something happens...cuz if something does happen -- IT WILL BE A ROCKET!
im leaving in about 25 min for vegas -- be back next week.
Lazarus
i have spoken with this company in the past...
they are essentially a shell.
i have been told that they ARE looking for a deal to put into the company.
Lazarus
what is the news???
the stock has a very low float
Lazarus
can you post the news...
...i dont see any...but i do notice that the stock is PERKING ;)
whatever the news is ... it must not be all that great based upon the volume.
Lazarus
im relatively new to ihub...
but have been trading penny stocks for several years.
my recollection is i have used it in public posts on other message boards. i dont recall using the term "perking stock" but rather making statements such as "ABCD is beginning to perk [or is perking up]."
FWIW over the years i have tried to maintain the same name on all public message boards: Lazarus - which is my Christian name. i used to be Lazarus on RB but lost it years ago when they did a server update or some such thing and had to take a variation thereof so now its lazarus39. i am also Lazarus on SI.
Lazarus - aka Captain PotatoHead the ORIGINAL spud muffin
i have been using "perking" for years...
...maybe YOU have been reading MY posts!
easy does it there cowboy....
....throwing' the filings in our face like that aint fair. if we start havin' to read all the crap on these companies --- we might get our panties in a wad and not buy 'em up.
now if its OK with you --- we'd like to just savor the NEWS.
Lazarus
agreed :)
golad to hear...
that was so friggin bazaar!
look at the way they spread EACI after they returned my shares...
http://www.pinksheets.com/quote/quote.jsp?symbol=eaci
lol
Form 10KSB for CELOX LABORATORIES INC
--------------------------------------------------------------------------------
1-Dec-2003
Annual Report
Item 6 — Management's Discussion and Analysis or Plan of Operation
The following pertains to the results of operations and financial position of the Company for the two fiscal years ended August 31, 2003 and August 31, 2002 and should be read in conjunction with the financial statements included elsewhere herein.
Results of Operations
The Company had a net loss of $96,494 in fiscal 2003 compared to net loss of $204,302 in fiscal 2002. A large increase in sales with improved profit margins contributed to the decreased loss for fiscal 2003.
Net sales increased 23% or $94,843 to $503,754 in fiscal 2003 from $408,911 in fiscal 2002, primarily due to sales of cord blood related products, the timing of orders received from manufacturing customers and the amount and timing of distributors orders. Two customers accounted for sales of more than 10% of the Company's annual sales in fiscal 2003. In fiscal 2002 one customer accounted for more than 10% of Company sales. (See Note 11 of Notes to Financial Statements.)
The Company also received interest income of $3,422 in fiscal 2003 compared to $6,589 in fiscal 2002 This is primarily due to the Company's cash position as a result of its March 1992 initial public offering and subsequent private placements. The decrease between years is due to the use of cash in operations coupled with significantly lower effective interest rates on investments.
A portion of the proceeds from the March 1992 initial public offering had been invested in the Piper Jaffray Institutional Government Income Fund. Due to an unexpected decline in value of the Fund, which was attributed to the purchase of derivatives, class action litigation by investors began in 1994. In February 1995, Piper Jaffray Companies Inc. announced a $70 million (less attorney fees) settlement to settle such litigation, subject to court approval and acceptance of the settlement by a large percentage of the Funds' shareholders. In August 1995, a federal judge gave preliminary approval to this settlement, which was a combination of $20 million in cash and $50 million in 8% notes payable. All payments were received from Piper Jaffray in accordance with the schedule outlined by the court. Litigation by investors against auditors of the Fund related to Fund losses was settled in June 2000. In October 2000, the Company received a check in the amount of $20,539 from the KPMG Litigation Settlement fund, which was recognized as other income in fiscal 2001. A final residual payment was received in the first quarter of fiscal 2002 and was recognized as other income.
Sales and operations and general and administrative expenses increased by less than 1% or $792 from $312,681 in fiscal 2002 to $313,473 in fiscal 2003. The small increase between the respective periods was due to expense control and stable wages and health care costs.
Cost of goods sold decreased by $19,049 as compared to fiscal 2002, and represented 28% of sales in fiscal 2003 compared to 39% of sales in fiscal 2002 The decrease in the cost of goods sold as a percentage of sales results from a large increase in sales as well as the mix of products sold during the comparable periods as new product sales continued to increase and other products were discontinued.
Research and development expenses decreased by 1% or $971 to $146,264 in fiscal 2003 from $147,235 in fiscal 2002. The decrease between years results from the timing and amount of professional fees and other costs associated with the patent filing for ViaStem™ as well as salaries and wages related to advancing ViaStem™ through pre-clinical and clinical trials. The Company did not introduce any new products in fiscal 2003. The Company presently has 16 standard products in addition to a number of specialty manufactured products.
The basic and diluted loss per common share was ($0.02) in fiscal 2003 compared to ($0.05) in fiscal 2002.
In 2004, the Company will continue its efforts to increase sales volume through focused marketing activities and through sales of the cord blood related products. The sales and marketing activities will consist of seeking further relationships with independent sales organizations and distributors, expanding its distribution activities with MP Pharmaceuticals, and the Sigma Chemical Company and increased contract manufacturing. Newly introduced products will be marketed by the Company and potentially will be made available to one or more distributors. In addition, the Company will continue to focus on the sales of its proprietary products, which have better margins than the basal media and balanced salt solutions. The Company expects operating costs to increase in 2004 due to the expected costs of the clinical tests for ViaStem™ and International Patent costs for ViaStem™. However, there can be no assurance that sales will increase or that the Company will be profitable in the future. Management does not expect to realize an operating profit in fiscal 2004.
Liquidity and Capital Resources
During 2003, the Company had capital expenditures in the amount of $2,537. The Company anticipates that capital expenditures for 2003 will be approximately $20,000 to fund additional sales, research and development, and manufacturing growth. This amount does not include any expenditures for clinical investigation.
At August 31, 2003, the Company had cash and short-term investments totaling $201,466 This cash and short-term investment position is from the proceeds of the Company's March 1992 initial public offering as well as subsequent private placements in fiscal 1999, 2000 and 2001. Management believes that these funds in addition to product sales will be sufficient to fund operating losses and capital expenditures for fiscal 2004.
The Company is leasing approximately 9,500 square feet of office, laboratory and warehouse space in St. Paul, MN under a seven-year lease through April 2004 with an option of two, five year renewals. The Company moved into the new facility during March 1997. As partial payment for tenant improvements in the new facility, the Company borrowed $100,000 from a local bank. The loan is secured by a certificate of deposit at the bank. The interest rate for this loan (currently at 4%) is tied to the certificate of deposit rate. The loan was renewed in fiscal 2003 for a one year term with a maturity in February 2004. The balance of the tenant improvements over this amount was paid with Company funds.
During the third quarter of fiscal 2000 additional funds in the amount of $211,750 were raised by selling units at $1.15 per unit and common stock at $1.40 per share to other investors in a private placement. The additional funds raised were used for general corporate expenses as well as for advancing ViaStem™ through the necessary testing before FDA approval can be obtained.
The Company sold subscriptions for 157,659 shares of common stock with a warrant at $0.47 per unit in a private offering in August 2001. Common shares were issued for both those subscriptions as well as additional subscriptions sold during fiscal 2002.
The Company intends to pursue additional financing in fiscal 2004, subject to prevailing market conditions. The Board of Directors approved the issuance of up to 400,000 shares of Preferred Stock to be issued in a Private Placement in order to pursue additional financing. Proceeds raised will be intended to fund preclinical trials for ViaStem™ as well as for general corporate purpases. There is no guarantee however, that the Company will be able to successfully raise an adequate amount of additional funds. In addition, there can be no assurance that the Company will be able to obtain the necessary FDA approvals for ViaStem™.
At this time, management is not aware of any factors that would have a materially adverse impact on cash flow beyond fiscal 2004 other than the potential for continuing losses and the potential expenses associated with clinical trials for ViaStem™. Management expects operating losses to continue in fiscal 2004.
Effects of Inflation
The Company believes inflation will not have a significant impact on the Company's operations.
Seasonality
The Company's operations are not subject to seasonal fluctuations.
--------------------------------------------------------------------------------
yep :)
penny oils have been slowly creeping up...
BSIC - SPND - and ALTX
would like to see RMMI join the list [on fundementals mind you - hot hype or momo]
Lazarus
better is an expensive stock that gets more expensive...
than a cheap stock that gets cheaper.
[ancient Lazarian proverb.]
Lazarus
LMIT Share information.
As of the record date, July 18, 2003, there were approximately 21,714,490 shares of stock outstanding. Each outstanding share of Common Stock is entitled to one vote.
The following table sets forth certain information with respect to persons known to the Company to own beneficially more than five percent (5%) of the Company's voting securities, as of the record date, and persons who have served and/or are still serving as directors of the Company since the beginning of the last fiscal year, and the directors and officers of the Company as a group.
Amount and
Position Nature of Percent
Title of Name and Address of with Beneficial of
Class Beneficial Owner Company Ownership Class
Common BSI, Inc. n/a 11,000,000 00.0
4766 Holladay Blvd.
Holladay, Utah 84117
Common REA, LLC (1) n/a 2,000,000 0
4766 Holladay Blvd.
Holladay, Utah 84117
Common Scott Hosking (1) Dir. & Pres . 1,000,000 0
378 North Main, #124
Layton, Utah 84061
Management as a group (one) 1,000,000 0
(1) Shares have been pledged to a third party to secure a loan.
2. Changes in Control.
The Company is currently seeking business opportunities to acquire or merge with. The Company has investigated several opportunities, but has not entered into a definitive agreement to date. Changes in the composition of the Board of Directors, as well as changes in controlling ownership of the Company's voting stock, could be possible in the near future as the Company seeks business venture acquisitions or mergers.
Matters to be Consented To
1. Reverse Split.
As of the Record Date, the Company's stock has little or no public market for its common stock. Based upon current market conditions and NASDAQ listing requirements, and brokerage firm interest in low priced securities, management has determined that it is in the Company's best interest to effectuate a reverse split, which is to be authorized by the shareholders. The Board is seeking authority to effectuate up to a 200 to 1 reverse split, the final amount to be determined by the Board at a later date.
Fractional shares will be rounded up to the nearest full share. In an effort to preserve shareholders in "round lots", which is of benefit to the shareholders and the Company, no certificate below one hundred shares will be reversed and no certificate greater than one hundred shares will be reversed below one hundred shares.
As existing stock certificates are sent in for transfer they will be replaced with new certificates reflecting the reverse split.
2. Change in the Name of the Company.
The shareholders will vote to give the Board of Directors authority to change the name of the Company to a name to be selected at a later date.
Vote Required for Approval
Approval of the proposed above action requires a majority vote of the shareholders of shares as of the Record Date. Because shareholders holding a majority of the shares are in favor of the proposed actions, proxies are not being solicited in this matter and the corporate action will be approved by written shareholder consent.
---------------
. Share information.
As of the record date, July 18, 2003, there were approximately 21,714,490 shares of stock outstanding. Each outstanding share of Common Stock is entitled to one vote.
The following table sets forth certain information with respect to persons known to the Company to own beneficially more than five percent (5%) of the Company's voting securities, as of the record date, and persons who have served and/or are still serving as directors of the Company since the beginning of the last fiscal year, and the directors and officers of the Company as a group.
Amount and
Position Nature of Percent
Title of Name and Address of with Beneficial of
Class Beneficial Owner Company Ownership Class
Common BSI, Inc. n/a 11,000,000 00.0
4766 Holladay Blvd.
Holladay, Utah 84117
Common REA, LLC (1) n/a 2,000,000 0
4766 Holladay Blvd.
Holladay, Utah 84117
Common Scott Hosking (1) Dir. & Pres . 1,000,000 0
378 North Main, #124
Layton, Utah 84061
Management as a group (one) 1,000,000 0
(1) Shares have been pledged to a third party to secure a loan.
2. Changes in Control.
The Company is currently seeking business opportunities to acquire or merge with. The Company has investigated several opportunities, but has not entered into a definitive agreement to date. Changes in the composition of the Board of Directors, as well as changes in controlling ownership of the Company's voting stock, could be possible in the near future as the Company seeks business venture acquisitions or mergers.
Matters to be Consented To
1. Reverse Split.
As of the Record Date, the Company's stock has little or no public market for its common stock. Based upon current market conditions and NASDAQ listing requirements, and brokerage firm interest in low priced securities, management has determined that it is in the Company's best interest to effectuate a reverse split, which is to be authorized by the shareholders. The Board is seeking authority to effectuate up to a 200 to 1 reverse split, the final amount to be determined by the Board at a later date.
Fractional shares will be rounded up to the nearest full share. In an effort to preserve shareholders in "round lots", which is of benefit to the shareholders and the Company, no certificate below one hundred shares will be reversed and no certificate greater than one hundred shares will be reversed below one hundred shares.
As existing stock certificates are sent in for transfer they will be replaced with new certificates reflecting the reverse split.
2. Change in the Name of the Company.
The shareholders will vote to give the Board of Directors authority to change the name of the Company to a name to be selected at a later date.
Vote Required for Approval
Approval of the proposed above action requires a majority vote of the shareholders of shares as of the Record Date. Because shareholders holding a majority of the shares are in favor of the proposed actions, proxies are not being solicited in this matter and the corporate action will be approved by written shareholder consent.
---------------
do you think they will have a problem with getting a majority?
her's the link and good luck : http://www.sec.gov/Archives/edgar/data/23778/000002377803000008/deflumlite.htm
Lazarus
i dont think it will be very LIQUID after the split.
isnt LMIT scheduled for 1/200 rs?
Lazarus
isnt LMIT schedutled for a 1/200 rs?
Lazarus
and buy into weakness ...
PSCO
i hope this is the bottom.
hey - i got six kids and i REALLY have said that many times :)
funny thing is i am cooking some fresh mushroom soup [raining here in central cal] and i just popped in from the kitchen and caught this run.
well - if i would have known the stock was gonna run like that i might have bot the more expensive mushrooms :(
Lazarus
i actually prefer a stock that creeps up slowly on fundamentals. not complaining about the momo though.
i sold 90% of my shares of ECEC on that run...some at .20
Lazarus
when they are cutting the pizza and you are real hungry...
...dont you say "cut it into lots of pieces cuz im starving!"
Lazarus
gave them more at .20
no compelling reason to hold.
Lazarus
unreal - they ate 'em right up!
damn! they be gone too...